Cassady Schiller Wealth Management’s Neurocrine Biosciences NBIX Stock Holding History

Cassady Schiller Wealth Management’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	$1.5K	Buy	+11	New	+$1.36K	﹤0.01%	663

Other funds holding NBIX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Cassady Schiller Wealth Management's NBIX Position: Q4 2024 in Review

Cassady Schiller Wealth Management opened a new position in Neurocrine Biosciences (NBIX) in Q4 2024: 11 shares worth $1.5K. The stake represents ﹤0.01% of the portfolio and ranks #663 among its holdings.

600 funds tracked by Wall St. Rank hold NBIX as of Q4 2024.

Cassady Schiller Wealth Management held 11 shares of Neurocrine Biosciences worth $1.5K as of Q4 2024.
Neurocrine Biosciences was a new Cassady Schiller Wealth Management position in Q4 2024.
Neurocrine Biosciences made up ﹤0.01% of Cassady Schiller Wealth Management's portfolio in Q4 2024, its #663 holding.
600 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q4 2024.

Based on Cassady Schiller Wealth Management's 13F filing for Q4 2024, filed 10 Feb 2025.